GPC3 CAR T Cells for Brain Tumors

This trial tests a new treatment for individuals with certain brain tumors unresponsive to other therapies. The treatment uses modified T cells, known as RADIANT-T cells, designed to target and attack tumor cells. Specifically, it involves 21.15.GPC3-CAR T Cells, a type of immunotherapy. The trial aims to determine the safest dose and assess the effectiveness of these cells in fighting tumors. Ideal candidates have GPC3-positive brain tumors that are difficult to treat and have not improved with standard care. Participants should also maintain a stable condition and discontinue most medications for a few weeks before joining. As a Phase 1 trial, this research focuses on understanding the treatment's effects in people, offering participants the chance to be among the first to receive this innovative therapy.

The trial requires that you are not receiving any concurrent anti-cancer therapy and have a stable or decreasing dose of steroids. Additionally, there are specific washout periods for certain treatments, such as 14 days after small volume radiotherapy and 21 days or 5 half-lives after any prior systemic therapy. Please discuss your current medications with the trial team to ensure eligibility.

Research has shown that GPC3 CAR T cells, a type of specially modified immune cell, have been safe in past studies with patients who have GPC3-positive solid tumors. These cells are designed to find and destroy cancer cells. In other studies, similar CAR T cells have been safely administered to patients, but they didn't always effectively target tumors.

In laboratory settings, GPC3 CAR T cells combined with IL-15 and IL-21 have demonstrated greater effectiveness in killing tumor cells than those without these additions. IL-15 and IL-21 are proteins that enhance the longevity and efficacy of T cells. The treatment also includes a safety feature that allows doctors to halt it if necessary.

Unlike the standard treatments for brain tumors, which often include surgery, radiation, and chemotherapy, the 21.15.GPC3-CAR T Cell Therapy offers a groundbreaking approach. This treatment uses genetically engineered T cells that specifically target the GPC3 protein found on tumor cells, allowing for more precise attacks on the cancer. Additionally, these CAR T cells are enhanced with cytokines IL-15 and IL-21 to boost their effectiveness and persistence in the body. Researchers are excited because this method has the potential to directly and powerfully attack tumor cells while sparing healthy brain tissue, which could lead to more effective treatments with fewer side effects.

This trial will evaluate the use of 21.15.GPC3-CAR T cells, specially modified to fight cancer, in patients with brain tumors. Studies have shown that GPC3-CAR T cells have been tested in humans and initially appear safe. Research indicates that when administered directly into the brain, these T cells seem to attack tumor cells. In this trial, the T cells are enhanced with IL-15 and IL-21, proteins that boost T cell activity, making them more effective in killing cancer cells compared to CAR T cells without these proteins. In animal studies, these modified T cells demonstrated increased growth and activity against tumors. Early findings from other studies suggest that 66% of patients experienced disease control, and 33% showed an antitumor response, offering hope for this treatment's potential effectiveness against aggressive brain tumors.¹⁴⁵⁶⁷